Please see the agenda below to see all topics that will be covered.
| Tuesday | ||||||
|---|---|---|---|---|---|---|
| Start Time | End Time | Session | Topic | Facilitator | Faculty Presenting | Faculty Hospital |
| 7:30 AM | 8:00 AM | Registration / Breakfast | ||||
| 8:00 AM | 8:10 AM | Session 9: GI Leaks and Enterocutaneous Fistulae: Multidisciplinary Strategies for Closure and Control | Endoscopic closure of GI leaks and fistulae: over-the-scope clips, endoscopic suturing, and covered stents — patient selection and technique | Michael Terjimanian, MD & Ryan Juza, MD | Ryan Juza, MD | University of Wisconsin |
| 8:10 AM | 8:20 AM | IR-guided drainage and fistula management: percutaneous abscess control, fistulography, and tract embolization | Michael Terjimanian, MD | University of Michigan | ||
| 8:20 AM | 8:30 AM | Surgical management of gastrointestinal leaks: timing, source control, nutritional optimization, and definitive repair | Charudutt Paranjape, MD | Mass General Brigham | ||
| 8:30 AM | 8:45 AM | Panel discussion: the post-operative patient with an anastomotic leak, undrained collection, and high-output fistula | Ryan Juza, MD | University of Wisconsin | ||
| Michael Terjimanian, MD | University of Michigan | |||||
| Charudutt Paranjape, MD | Mass General Brigham | |||||
| 8:45 AM | 8:57 AM | Session 10: Pancreatic Cystic Neoplasms and Low-Grade Malignancies: Diagnosis, Surveillance, and Intervention | EUS-guided diagnosis and risk stratification of pancreatic cystic neoplasms: through-the-needle biopsy, cyst fluid analysis, and emerging molecular markers | Bill Sherk, MD & Kevin El-Hayek, MD, MBA, FACS | Linda Lee, MD | Brigham and Women’s Hospital |
| 8:57 AM | 9:09 AM | Endoscopic ablation of pancreatic cysts: EUS-guided ethanol and radiofrequency ablation — evidence and patient selection | Kumar Krishnan, MD | Massachusetts General Hospital | ||
| 9:09 AM | 9:21 AM | Surgical resection of pancreatic cystic neoplasms and low-grade malignancies: minimally invasive pancreatectomy, parenchymal-sparing approaches, and oncologic thresholds | Kevin El-Hayek MD, MBA, FACS | The MetroHealth System | ||
| 9:21 AM | 9:33 AM | IR management of post-pancreatectomy complications: Vascular | Bill Sherk, MD | University of Michigan | ||
| 9:33 AM | 9:45 AM | IR management of post-pancreatectomy complications: Non-Vascular | Keith Quencer, MD | OHSU | ||
| 9:45 AM | 10:00 AM | Panel discussion: the patient with a symptomatic 4 cm branch-duct IPMN and worrisome features | Ashley Faulx, MD | University Hospitals Cleveland Medical Center | ||
| Kumar Krishnan, MD | Massachusetts General Hospital | |||||
| Kevin El-Hayek MD, MBA, FACS | The MetroHealth System | |||||
| Bill Sherk, MD | University of Michigan | |||||
| 10:00 AM | 10:20 AM | Break and Vendor Visiting in Exhibit Lounge | ||||
| 10:20 AM | 11:00 AM | Session 11: Keynote Lecture | Advances in Transplant Oncology: Role of Multidisciplinary Patient Centered Care | Shimul Shah, MD | Mass General Brigham | |
| 11:00 AM | 11:10 AM | Session 12: Hepatocellular Carcinoma (HCC) | Early Hepatocellular Carcinoma in 2026: Expanding Curative Hepatic Resection with Parenchymal-Sparing Strategies, Minimally Invasive Approaches, and Long-Term Oncologic Outcomes | Eric Hoffer, MD & Martin Dib, MD | Martin Dib, MD | Beth Israel Deaconess Medical Center |
| 11:10 AM | 11:20 AM | Next-Generation Ablation: Thermal ablation, Histotripsy, Fusion Imaging, and Combination Locoregional Therapy for Early HCC | Paul Shyn, MD | Harvard Medical School, Brigham and Women’s Hospital | ||
| 11:20 AM | 11:30 AM | Liver Transplantation for HCC in the Era of Expanded Criteria: Downstaging, Biology-Based Selection, and Bridging Innovation | Teresa Rice, MD | Mass General Brigham | ||
| 11:30 AM | 11:40 AM | Beyond TACE: Y-90 Radiation Segmentectomy, Personalized Dosimetry, and Systemic Integration in Advanced HCC | Suvranu Ganguli, MD | Boston Medial Center/Boston University School of Medicine | ||
| 11:40 AM | 11:50 AM | The Hepatologist’s Role in Modern HCC Management: Risk Stratification, Liver Function Optimization, and Guiding Curative-Intent Multidisciplinary Therapy | Irun Bhan, MD | Massachusetts General Hospital | ||
| 11:50 AM | 12:00 PM | Noon Immunotherapy Revolution in HCC: IO + VEGF Combinations, Peri-Transplant Considerations, and Emerging Biomarkers | Kelsey Lau-Min, MD | Mass General Brigham Cancer Institute | ||
| 12:00 PM | 1:00 PM | Hands on Workshop & Lunch | Liquid Embolics | Sirtex | Ke Zhang, MD PhD | Brigham and Women’s Hospital |
| Suvranu Ganguli, MD | Boston Medial Center/Boston University School of Medicine | |||||
| 1:00 PM | 1:45 PM | Session 13: Multidisciplinary Tumor Board II – HCC | Multidisciplinary Tumor Board I – HCC, Curative Intent and Transplant Decision-Making | Kevin Kim, MD & Boris Hristov, MD | Martin Dib, MD | Beth Israel Deaconess Medical Center |
| Baljendra Kapoor, MD | University of Michigan | |||||
| Paul Shyn, MD | Harvard Medical School, Brigham and Women’s Hospital | |||||
| Suvranu Ganguli, MD | Boston Medial Center/Boston University School of Medicine | |||||
| Ameer Elaimy, MD PhD | University of Michigan | |||||
| Kelsey Lau-Min, MD | Mass General Brigham Cancer Institute | |||||
| Nataliya Razumilava, MD | University of Michigan | |||||
| 1:45 PM | 1:55 PM | Session 14: Cholangiocarcinoma | Surgery for Cholangiocarcinoma in 2026: Defining Resectability, Complex Hepatectomy, and Curative-Intent Strategy | Manish Varma, MD & Raul Uppot, MD | Manish Varma, MD | Tufts Medical Center, Boston, MA |
| 1:55 PM | 2:05 PM | Liver-Directed Therapy for Cholangiocarcinoma: Y-90, Arterial Infusion, and Conversion to Resection Strategies | Neal Viradia, MD | University of Miami/Bruce Carter VA | ||
| 2:05 PM | 2:15 PM | Radiation Therapy in Cholangiocarcinoma: From Definitive Local Control to Neoadjuvant Bridge and Oligoprogression Management | Hannah Roberts, MD | Mass General Brigham | ||
| 2:15 PM | 2:25 PM | Precision Oncology in Cholangiocarcinoma: Targeted Therapy, Molecular Subtyping, and Clinical Trial-Driven Treatment Selection | Andrea Bullock, MD MPH | Beth Israel Deaconess Medical Center | ||
| 2:25 PM | 3:00 PM | Session 15: Multidisciplinary Tumor Board III – Cholangiocarcinoma | Multidisciplinary Tumor Board II – Cholangiocarcinoma, Complex Biliary Malignancy Management | Charles Kim, MD & Manish Varma, MD | Kumar Krishnan, MD | Massachusetts General Hospital |
| Manish Varma, MD | Tufts Medical Center, Boston, MA | |||||
| Steve Huang, MD | The University of Texas MD Anderson | |||||
| Andrea Bullock, MD MPH | Beth Israel Deaconess Medical Center | |||||
| Hannah Roberts, MD | Mass General Brigham | |||||
| 3:00 PM | 3:30 PM | Break and Vendor Visiting in Exhibit Lounge | ||||
| 3:30 PM | 3:40 PM | Session 16: Neuroendocrine Tumors (NET) | Surgical Cytoreduction for NET Liver Metastases: Defining the Modern Threshold for Aggressive Liver Debulking | John Kachura, MD FSIR & James Frencher, MD | Eduardo Vega, MD | Boston Medical Center |
| 3:40 PM | 3:50 PM | Embolotherapy for NET Liver Metastases: Optimizing TAE, TACE, and Y-90 for Durable Disease Control and Symptom Palliation | James Frencher, MD | University of Michigan Medical School | ||
| 3:50 PM | 4:00 PM | PRRT and Systemic Therapy Integration in NETs: Sequencing Theranostics, Somatostatin Analogs, and Targeted Agents for Liver-Dominant Disease | Jennifer Chan, MD | Dana-Farber Cancer Institute | ||
| 4:00 PM | 4:30 PM | Session 17: Multidisciplinary Tumor Board IV – NETs | Multidisciplinary Tumor Board III NETs, Cytoreduction vs Disease Control Strategy | Suvranu Ganguli, MD & Jennifer Chan, MD | Eduardo Vega, MD | Boston Medical Center |
| Eric Wehrenberg-Klee, MD | Massachusetts General Hospital | |||||
| John Kachura, MD, FSIR | Toronto General Hospital | |||||
| Jennifer Chan, MD | Dana-Farber Cancer Institute | |||||
| Boris Hristov, MD | University of Michigan | |||||
| 4:30 PM | 5:30 PM | Session 18: My Best Save | Case 1 | Sid Tavri, MD & Dan Patel, MD | Ajinkya Desai, MD | Massachusetts General Hospital |
| Case 2 | Alexander Vezeridis, MD | Stanford | ||||
| Case 4 | Keith Quencer, MD | OHSU | ||||
| Case 5 | Lauren Ferrara, MD | UMass Chan Medical School | ||||
| Case 6 | Nick Befera, MD | Duke University | ||||
| 5:30 PM | 5:35 PM | Session 19: Best Abstract Award | Resmi Charalel, MD MPH FSIR | Montefiore Einstein |